Breathing New Life into Immunisation Policies: Enhancing Prevention of RSV and Pneumococcal Disease
INSIDE VIEW: Robert Cohen & Susan Hepworth
@espid.bsky.social #ESPID2025
healthpolicy-watch.news/breathing-ne...
Can Kangaroo Care save lives AND prevent infection in low-birthweight infants? 🦘🧑🍼
A systematic review of 17,500+ low birthweight across 29 trials, shared at #ESPID2025 by our #NeoIPC team, shows it’s a true game-changer!
View poster: neoipc.org/wp-content/u...
Do #COVID resitrictions affect kids more than adults? 🧒👨
A #VERDI study in Estonia, presented at #ESPID2025, found:
✔️ Workplace closures reduced spread
✔️ Fewer tests = fewer reported kid cases
✔️ Travel didn’t impact transmission
✔️ Case incidence? Similar for kids & adults
Poster 👉 lnkd.in/dgEQ54pF
Hot from #ESPID2025: Cell-based flu vaccine significantly better than egg-based for children.
Read the full study: www.emjreviews.com/microbiology...
✨An extraordinary week at #ESPID2025 in Bucharest—the first major #ID event in 🇷🇴, with 3000+ participants!
Honored to have given a keynote on #ViralHepatitis to an engaged audience. A powerful reminder: science transcends borders & thrives on collaboration. 🌍🧠
Proud to be part of Team-COACH—and even prouder to see our the project showcased at #ESPID2025!
We're supporting healthcare teams with training to prevent infections and use antibiotics wisely, helping improve health outcomes for children.
#ChildHealth #IPC #AMS
Penta & the Prevent Syphilis project co-hosted a vital session on congenital syphilis at #ESPID2025.
This growing but often overlooked public health issue deserves attention & we were proud to spotlight it.
#PreventSyphilis #Paediatrics #InfectiousDiseases #GlobalHealth #PublicHealth
🧵 1/4
At #ESPID2025, the Penta Respiratory Infections Working Group shared new insights on how paediatricians across Europe view infant RSV prevention tools, including a single-dose antibody + the maternal RSV vaccine.
But how do doctors feel about using them?
Check-out our project #Team-COACH at yesterday´s #ESPID2025 Research Session 🧑🏫
Our work focuses on training for improving practices in #IPC and #AMS in the pediatric population 👶
We love engaging with more healthcare professionals to spread our mission 🏥 #PaediatricInfectiousDisease
Excellent session on #AntimicrobialStewardship training programmes.
Inspiring to see how impactful
TEAM-COACH
has already been - over 1000 healthcare workers engaged so far! 👏
#InfectionPrevention #AMR #AMS
#ESPID2025 #ESPIDInspires
🎓Yesterday, our colleage Serena Villaverde presented our project Team-COACH at #ESPID2025!
She shared insights on how clinical practice indicators changed before and after using our e-learning tool during the pilot phase 📊✨
#PediatricInfectiousDisease #AMS #IPC
Only the best of the very best here in Bucharest at #ESPID2025 👏👏👏
Privileged to deliver one of the debate sessions today - on postnatal prophylaxis of the #HIV in newborns!
Had so much fun - huge thanks to the #YoungESPID team!
Already looking forward to the next one!
#ESPID2025 #ESPIDInspires
Final presentation in this session by Vera Buerger describing their phase 3 trial results for a chikungunya vaccine in Brazilian adolescents
Persistent protective seroresponse was observed after 1 year in 98% of participants.
#ESPID2025
Andrea Guerra from MSD is presenting the safety and efficacy of clesrovimab against RSV in infants.
#ESPID2025
Hello Bucharest!
GARDP's Peter Beyer was at #ESPID2025 to talk about our efforts to tackle neonatal sepsis.
"When it comes to antibiotic resistance in children, can we make a positive impact? GARDP’s response is a resounding YES. It starts with putting children at the centre of our AMR response."
#ESPID2025
New Vaccines in Town:
Paratyphoid vaccine could become the first to be licensed on basis of controlled human infection model (CHIM) - great talk by Andrew Pollard
Paul Heath from the UK is now presenting on the development of Group B Strep vaccines.
GBS #vaccines will not only impact the incidence of neonatal sepsis, but reduce antibiotic exposure, disruption to microbiome and #AMR
#ESPID2025
A bivalent typhoid-paratyphoid conjugate vaccine is being developed, with phase I trials completed.
The introduction of these vaccines will change the shape of enteric fevers. However we shouldn't forget that if people had access to clean water these infections wouldn't occur.
#ESPID2025
There is concern that with the roll out of Typhoid vaccines it will be replaced with Paratyphoid infections, with previous evidence alluding to this.
A live attenuated oral #vaccine for Paratyphoid is currently in trials, with ~70% efficacy in challenge models
#ESPID2025
The WHO has approved the use of the typhoid conjugate vaccine for all children <15 years, however rollout was impacted by the pandemic.
Real-world studies have shown the vaccine has ~80% effectiveness against Typhoid fever. However, no evidence of herd immunity was observed.
#ESPID2025
Next up is Andrew Pollard @ajpollard1.bsky.social from the UK discussing Typhoid and Paratyphoid vaccines
Vaccines for Tyhpoid were first developed for Boer War troops, but very reactegenic and poorly accepted.
Typhoid #vaccines often used for travellers rather than high burden areas
#ESPID2025
During the MVIP Pilot with RTS,S there was a 13% vaccine-attributable reduction in all cause mortality observed, with a 22% reduction in hospitalised severe malaria.
Mixing the #vaccine with treated nets and seasonal chemoprophylaxis, #malaria incidence can be reduced by 92%
#ESPID2025
This afternoon I'm sitting in the New Vaccines symposium at #ESPID2025.
First up is Mary Hamel from WHO describing the Malarial #vaccine Implementation Program, including use of the RTS,S vaccine
During the MVIP trial in 2019-23, 2 million children were vaccinated in Kenya, Ghana, and Malawi
The STOP trial aimed to and achieved a 50% reduction in impetigo in children over the study period. This landmark trial included co-design of health promotion materials and interpretation of findings. These results lead to the development of National Healthy Skin Guidelines in Australia
#ESPID2025
Often Group A Strep is the causative pathogen for skin and soft tissue infections. Even when Staph is detected, it's often a colonising organism. @ashabowen.bsky.social and team found that co-trimoxazole is an appropriate alternative to Pen G for these infections in Australian children
#ESPID2025
Features of poverty are correlated with increased rates of skin or soft tissue infections. These may lead to significant secondary infections and morbidity. Patients often face stigmatisation, and infections in children of colour are often missed due to systemic racism.
#ESPID2025 #MedSky
A photo from the back of a theatre with the audience looking at a large presentation screen on the stage
In the Antibiotic Use in Ambulatory Care session at #ESPID2025, @ashabowen.bsky.social from the @wcvid.bsky.social and @thekidsau.bsky.social is presenting on the importance of skin and soft tissue infections and why it matters for #AMR
Dona and colleagues found that although most centres did not exclude colonisation for transplantation, more than half did not have a decolonisation strategy.
Cephalosporins accounted for ~50% of monotherapy, and ~40% of centres prescribe antifungal prophylaxis
#ESPID2025 #IPC #MedSky
